One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Sarcopenia and cancer-related inflammation measurements in advanced gastric and junctional cancers—ready for prime time?
S.Arulananda12E.Segelov12
Bigger isn't always better: the ESMO dose de-intensification guideline framework
C.L.Shapiro
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer
S.Filetti1C.Durante2D.M.Hartl34S.Leboulleux56L.D.Locati78K.Newbold9M.G.Papotti10A.Berruti11ESMO Guidelines Committee
Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial
U.T.Hacker1†D.Hasenclever2†R.Baber34N.Linder5H.Busse5R.Obermannova67L.Zdrazilova-Dubska78D.Valik78F.Lordick1
The age-dependent association of risk factors with pancreatic cancer
C.Yuan1J.Kim2Q.L.Wang1A.A.Lee3A.Babic1
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification
D.Trapani12†M.A.Franzoi3†H.J.Burstein2L.A.Carey4S.Delaloge5N.Harbeck6D.F.Hayes7K.Kalinsky8L.Pusztai9M.M.Regan10I.Sestak11T.Spanic12J.Sparano13S.Jezdic14N.Cherny15G.Curigliano16F.Andre3
Cancer risk in individuals with autism spectrum disorder
Q.Liu1W.Yin1J.J.Meijsen2A.Reichenberg34J.R.GÃ¥din2A.J.Schork2H.-O.Adami567A.Kolevzon348S.Sandin345†F.Fang1â€
Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS)
A.Zer1O.Icht2L.Yosef2D.Avram2O.Jacobi2E.Fenig2N.Kurman2I.Peretz2S.Shamai³O.Merimsky³E.Ben-Ami�R.Shapira Frommer�A.E.Schwarzbach5H.Bernstine6R.Weitzen7O.Vornicova8G.Bar-Sela8S.M.Stemmer2M.Lotem9
HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade
X.M.Shao12J.Huang1N.Niknafs3A.Balan3C.Cherry3J.White3V.E.Velculescu13V.Anagnostou3R.Karchin123
Reply to the Letter to the Editor ‘Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple-negative breast cancer’ by A. Okines and N. Turner
C.E.GeyerJr.1W.M.Sikov2S.Loibl3
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study
F.Nelli1D.Giannarelli2A.Fabbri1M.A.Silvestri3J. R. GironBerrios1A.Virtuoso1E.Marrucci1M.Schirripa1M.Mazzotta1A.Onorato1V.Panichi3G.Topini3G.Pessina4F.Natoni4C.Signorelli1M.G.Chilelli1F.Primi1E.M.Ruggeri1
Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study�: [Annals of Oncology (2019), volume 30:1279-1288]
S.Loibl12M.Untch3N.Burchardi1J.Huober4B.V.Sinn56J.-U.Blohmer7E.-M.Grischke8J.Furlanetto1H.Tesch2C.Hanusch9K.Engels10M.Rezai11C.Jackisch12W.D.Schmitt5G.von Minckwitz1J.Thomalla13S.Kümmel14B.Rautenberg15…A.Schneeweiss18
